Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
SER-155 by Seres Therapeutics for Graft Versus Host Disease (GVHD): Likelihood of Approval
SER-155 is under clinical development by Seres Therapeutics and currently in Phase I for Graft Versus Host Disease (GVHD). According...
Data Insights
SER-155 by Seres Therapeutics for Bacteremia: Likelihood of Approval
SER-155 is under clinical development by Seres Therapeutics and currently in Phase I for Bacteremia. According to GlobalData, Phase I...